Abstracts Archive - Page 2113 of 2425 - ACR Meeting Abstracts

Abstract Number: 2078 • 2013 ACR/ARHP Annual Meeting
Pulmonary Hypertension In Anti-Jo1 Syndrome
Nilofar Syed¹, Ruchi Yadav², Colin O'Rourke³ and Soumya Chatterjee⁴, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Diagnostic Radiology, Cleveland Clinic, Cleveland, OH, ³Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ⁴Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH
Background/Purpose: Antisynthetase syndrome is characterized by fever, myositis, interstitial lung disease (ILD), inflammatory arthritis, mechanic's hands, and Raynaud phenomenon. The most commonly reported form of…
Abstract Number: 2079 • 2013 ACR/ARHP Annual Meeting
Serum Interferon α, β and Interleukin-18 Are Associated With Disease Activity Of Rapidly Progressive Interstitial Lung Disease In Patients With Clinical Amyopathic Dermatomyositis
Shinji Sato¹, Noriko Sasaki¹, Shinichi Nogi¹, Naofumi Chinen², Kiri Honda¹, Eiko Saito¹, Chiho Yamada² and Yasuo Suzuki², ¹Rheumatology, Tokai University School of Medicine, Isehara, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
Background/Purpose: It is well known that rapidly progressive interstitial lung disease (RP-ILD) in patients with dermatomyositis (DM) is associated with poor outcome. Previous findings suggested…
Abstract Number: 2080 • 2013 ACR/ARHP Annual Meeting
Pregnancy Outcomes In Adult Patients With Dermatomyositis and Polymyositis
Lorinda Chung¹, David Fiorentino², Shufeng Li³ and Eliza Chakravarty⁴, ¹Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, ²Dermatology, Stanford University School of Medicine, Redwood City, CA, ³Dermatology, Stanford University School of Medicine, Palo Alto, CA, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM) are autoimmune inflammatory myopathies that frequently affect females of child-bearing potential. Small studies have indicated that active disease during…
Abstract Number: 2081 • 2013 ACR/ARHP Annual Meeting
Role Of Muscle Persistent CD28null T Cells In Glucocorticoid Therapy Resistance In Myositis Patients
Jayesh Pandya¹, Ingela M. Loell², Mohammad Shahadat Hossain², Mei Zong², Sukanya Raghavan², Ingrid E. Lundberg³ and Vivianne Malmström², ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are characterized by infiltration of T cells and macrophages in skeletal muscle tissue. Conventional immunosuppressive treatment has limited effects…
Abstract Number: 2082 • 2013 ACR/ARHP Annual Meeting
Interferon-Regulated Chemokine and Innate Cytokine Scores Identify Refractory Myositis Patients That Respond Better To Rtuximab Therapy
Consuelo Lopez de Padilla¹, Cynthia S. Crowson², Molly S. Hein³, Helen Khun², Rohit Aggarwal⁴, Marc C. Levesque⁵, Dana P. Ascherman⁶, Chester V. Oddis⁷ and Ann M. Reed³, ¹Rheumatology/Immunology Research, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Medicine / Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Medicine/Rheumatology, University of Miami, Miami, FL, ⁷Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Serum cytokines play an important role in the pathogenesis of myositis by initiating and perpetuating various cellular and humoral autoimmune processes. The aim of…
Abstract Number: 2083 • 2013 ACR/ARHP Annual Meeting
Environmental Factors Associated With Disease Flare In Juvenile and Adult Dermatomyositis
Gulnara Mamyrova¹, Lisa G. Rider², Olcay Jones³, Alison Ehrlich⁴, Lauren M. Pachman⁵, Robert Nickeson⁶, Lisa G. Criscione-Schreiber⁷, Frederick W. Miller², Lawrence K. Jung⁸ and James D. Katz¹, ¹Rheumatology, George Washington University, Washington, DC, ²Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ³Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD, ⁴Dermatology, The George Washington University, Washington, DC, ⁵Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Pediatrics, All Children's Hospital, St Petersburg, FL, ⁷Dept of Med/Rheum Div, Duke University School of Medicine, Durham, NC, ⁸Pediatric Rheumatology, Children's National Medical Center, Washington, DC
Background/Purpose: To assess environmental factors in relationship to increased disease activity (flare) in juvenile and adult dermatomyositis (DM). Methods: An online survey was conducted for…
Abstract Number: 2084 • 2013 ACR/ARHP Annual Meeting
Increasing Incidence Of Immune Mediated Necrotizing Myopathy In A Single Center
Martin Klein¹, Herman F. Mann², Josef Zámecník³ and Jiri Vencovsky⁴, ¹Institute of Rheumatology, Prague, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ³Department of Pathology and Molecular Medicine, 2nd Medical School and University Hospital Motol, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Institute of Rheumatology, Prague, Czech Republic
Background/Purpose: Immune mediated necrotizing myopathy (IMNM), characterized histologically by predominant myofiber necrosis with minimal or no inflammatory infiltrate and clinically by response to immunosuppressive therapy,…
Abstract Number: 2085 • 2013 ACR/ARHP Annual Meeting
Identification Of Clinical Features and Risk Factors Associated With Calcinosis In Adult Patients With Dermatomyositis
Antonia Valenzuela¹, Lorinda Chung², Livia Casciola-Rosen³, Antony Rosen³ and David Fiorentino⁴, ¹Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ²Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ³Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Dermatology, Stanford University School of Medicine, Redwood City, CA
Background/Purpose: Prior studies have estimated that 20% of adult dermatomyositis (DM) patients suffer from calcinosis. Although calcinosis is related to persistent disease activity, poor treatment…
Abstract Number: 2086 • 2013 ACR/ARHP Annual Meeting
Defining The Prevalence and Associated Risk Factors For Calcinosis In Adult Dermatomyositis Patients
Jessie Werner¹, Jason Liebowitz², Andrew L. Mammen³ and Lisa Christopher-Stine⁴, ¹Medicine, University of Maryland School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³NIAMS, NIH, Bethesda, MD, ⁴Medicine and Neurology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Calcinosis is known to be associated with junvenile dermatomyositis, but the prevalence and risk factors associated with the development of calcinosis in adult dermatomyositis…
Abstract Number: 2087 • 2013 ACR/ARHP Annual Meeting
Utility and Reliability Of Digital Nailfold Capillaroscopy In Children With Juvenile Dermatomyositis: Three Methods
Gabrielle A. Morgan¹, Adam Ostrower¹, Chiang-Ching Huang² and Lauren M. Pachman^1,3, ¹Cure JM Myositis Center, Ann & Robert H. Lurie Children's Hospital of Chicago Research Center, Chicago, IL, ²Zilber School of Public Health, University of Wisconsin at Milwaukee, Milwaukee, WI, ³Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Nailfold Capillaroscopy (NFC) is a non-invasive assessment of the nailfold area of the fingers which aids in the diagnosis of Juvenile Dermatomyositis (JDM) by…
Abstract Number: 2088 • 2013 ACR/ARHP Annual Meeting
The Percentage Of Th17 Cells Correlates with the Expression Of Microrna-206 In Patients With Dermatomyositis
Xinyi Tang¹ and Shengjun Wang², ¹Department of Laboratory Medicine, Jiangsu University Affi�liated People’s Hospital, Zhenjiang, China, ²Department of Immunology, Department of Immunology, Jiangsu University, Zhenjiang, China
Background/Purpose: DM (dermatomyositis) is a subtype of inflammatory myopathies，which is a rare autoimmune disease of skeletal muscle. Although the pathogenic mechanism of DM is still…
Abstract Number: 2049 • 2013 ACR/ARHP Annual Meeting
Comparison Of Corticosteroid Plus Lidocaine Or Lidocaine Alone In Patients Receiving Celecoxib For The Treatment Of Acute Shoulder Or Trochanteric Bursitis: A Randomized, Double-Blind, Placebo Controlled Trial
Muhammad Imran¹, Haritha Narla², Jo A. Wick³ and Herbert B. Lindsley⁴, ¹Rheumatology, Kansas University Medical center, Kansas city, MO, ²Rheumatology, Kansas university Medical Center, kansas city, MO, ³Biostatistics, Kansas University Med Ctr, Kansas City, KS, ⁴Medicine, Kansas University Med Ctr, Kansas City, KS
Background/Purpose: Bursitis is a self-limiting disorder in the majority of patients and typically responds to conservative measures. However, corticosteroid injections may be necessary in recurrent…
Abstract Number: 2050 • 2013 ACR/ARHP Annual Meeting
Arthralgia Occurring Under Aromatase Inhibitor Treatment For Breast Cancer. A Prospective Study
Daniel Wendling¹, Helene Letho-Gyselinck¹, Xavier Guillot², Clément Prati³ and Xavier Pivot⁴, ¹Service de Rhumatologie, Minjoz University Hospital, Besancon, France, ²Department of Rheumatology, CHRU Besançon, Besançon, France, ³Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁴Oncology, CHRU Besançon, Besançon, France
Background/Purpose: Treatment with third generation aromatase inhibitors (AI) is associated with occurrence of arthralgia, with an incidence ranging from 25 to 45 %. In these…
Abstract Number: 2051 • 2013 ACR/ARHP Annual Meeting
Characteristics and Comparison Of Patients With Cystic Fibrosis With and Without Arthritis
Heather O. Tory¹, Karen Herlyn², David Zurakowski³, Angela S. Pizzo⁴, Robert P. Sundel⁵ and Peter A. Merkel⁶, ¹Rheumatology Program, Division of Immunology, Boston Children's Hospital, Boston, MA, ²Department of Rheumatology, University Hospital Schleswig-Holstein, Lübeck, Germany, ³Departments of Anesthesia and Surgery, Boston Children’s Hospital, Boston, MA, ⁴Mercy Hospital, Portland, ME, ⁵Division of Immunology, Boston Children's Hospital, Boston, MA, ⁶Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cystic Fibrosis (CF) is a common genetic mutation in Caucasian populations. Many patients have musculoskeletal complaints and 12% develop arthritis, including CF arthropathy (CFA),…
Abstract Number: 2052 • 2013 ACR/ARHP Annual Meeting
The Prevalence and Pattern Of Self Reported Joint Symptoms In Cystic Fibrosis
Carl Orr¹, Cormac McCarthy¹, Johan Meurling¹, Paul G. O'Connell², Cedric Gunaratnam^1,3 and Noel G McElvaney¹, ¹Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland, ²Rheumatology, Beaumont Hospital, Dublin, Ireland, ³Department of Respiratory Medicine, Beaumont Hospital, Dublin, Ireland
Background/Purpose: Arthritis in cystic fibrosis (CF) can be very incapacitating, and it is mainly of three types: CF arthritis, hypertrophic osteoarthropathy, and arthritis due to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].